Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $11.1 million.

  • InMed Pharmaceuticals' Cash & Equivalents rose 68.37% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 68.37%. This contributed to the annual value of $11.1 million for FY2025, which is 68.54% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Cash & Equivalents of $11.1 million as of FY2025, which was up 68.54% from $6.6 million recorded in FY2024.
  • Over the past 5 years, InMed Pharmaceuticals' Cash & Equivalents peaked at $11.1 million during FY2025, and registered a low of $6.2 million during FY2022.
  • Over the past 3 years, InMed Pharmaceuticals' median Cash & Equivalents value was $8.9 million (recorded in 2023), while the average stood at $8.9 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first fell by 26.27% in 2024, then skyrocketed by 68.54% in 2025.
  • Yearly analysis of 4 years shows InMed Pharmaceuticals' Cash & Equivalents stood at $6.2 million in 2022, then skyrocketed by 44.29% to $8.9 million in 2023, then declined by 26.27% to $6.6 million in 2024, then spiked by 68.54% to $11.1 million in 2025.